Journal article
The Economic Value of a New Insulin Preparation, Humalog® Mix 25™
Abstract
Objective:To measure the economic value of a new insulin formulation consisting of rapid-acting insulin lispro and intermediate-acting neutral protamine lispro in a 25: 75 ratio (Humalog® Mix 25™).Design and Setting: A cost-benefit analysis using a consumer-based willingness-to- pay (WTP) approach was used. The study sample consisted of 80 Canadian taxpayers randomly selected from Ontario and Quebec. After background information on the …
Authors
Dranitsaris G; Longo CJ; Grossman LD
Journal
PharmacoEconomics, Vol. 18, No. 3, pp. 275–287
Publisher
Springer Nature
Publication Date
September 2000
DOI
10.2165/00019053-200018030-00007
ISSN
1170-7690